Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Zhang, Zhiyu ^c   Zhang, Lijun ^b   Hua, Yingqi ^a,d   Jia, Xiaofang ^b   Li, Jian ^d   Hu, Shuo ^d   Peng, Xia ^b   Yang, Pengyuan ^e   Sun, Mengxiong ^d   Ma, Fang ^b   Cai, Zhengdong ^a,d  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI PUBLIC HEALTH CLINICAL CENTER   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD151 ANTIGEN; MEMBRANE PROTEIN; CATION EXCHANGE RESIN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ARTICLE; CELL ADHESION; CELL STRUCTURE; CONTROLLED STUDY; EARLY DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION; BIOLOGY; BONE TUMOR; COMPARATIVE STUDY; ION EXCHANGE CHROMATOGRAPHY; METABOLISM; METHODOLOGY; PEPTIDE MAPPING; PILOT STUDY; PROTEIN ANALYSIS; PROTEIN DATABASE; PROTEIN DOMAIN; REPRODUCIBILITY; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE;

ANTIGENS, CD; BONE NEOPLASMS; CATION EXCHANGE RESINS; CELL LINE, TUMOR; CHROMATOGRAPHY, ION EXCHANGE; CHROMATOGRAPHY, REVERSE-PHASE; COMPUTATIONAL BIOLOGY; DATABASES, PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; OSTEOBLASTS; OSTEOSARCOMA; PEPTIDE MAPPING; PILOT PROJECTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 77952016443     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-206     Document Type: Article

References (43)

1. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 2007, 19(4):341-346. 10.1097/CCO.0b013e328122d73f, 17545797.
2. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here?. Paediatr Drugs 2008, 10(5):315-327. 10.2165/00148581-200810050-00005, 18754698.
3. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004, (429):286-291. 10.1097/01.blo.0000145991.65770.e6, 15577500.
4. Guo QC, Shen JN, Jin S, Wang J, Huang G, Zhang LJ, Huang G, Yin JQ, Zou CY, Li MT. Comparative proteomic analysis of human osteosarcoma and SV40-immortalized normal osteoblastic cell lines. Acta Pharmacol Sin 2007, 28(6):850-858. 10.1111/j.1745-7254.2007.00603.x, 17506944.
5. Folio C, Mora MI, Zalacain M, Corrales FJ, Segura V, Sierrasesumaga L, Toledo G, San-Julian M, Patino-Garcia A. Proteomic Analysis of Chemonaive Pediatric Osteosarcomas and Corresponding Normal Bone Reveals Multiple Altered Molecular Targets. J Proteome Res 2009,
6. Kawai A, Kondo T, Suehara Y, Kikuta K, Hirohashi S. Global protein-expression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res 2008, 466(9):2099-2106. 10.1007/s11999-008-0330-4, 2493021, 18535868.
7. Niforou KM, Anagnostopoulos AK, Vougas K, Kittas C, Gorgoulis VG, Tsangaris GT. The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genomics Proteomics 2008, 5(1):63-78.
8. Li G, Zhang W, Zeng H, Chen L, Wang W, Liu J, Zhang Z, Cai Z. An integrative multi-platform analysis for discovering biomarkers of osteosarcoma. BMC Cancer 2009, 9:150. 10.1186/1471-2407-9-150, 2691408, 19445706.
9. Faca VM, Hanash SM. In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res 2009, 69(3):728-730. 10.1158/0008-5472.CAN-08-3087, 19155298.
10. Lubke T, Lobel P, Sleat DE. Proteomics of the lysosome. Biochim Biophys Acta 2009, 1793(4):625-635. 10.1016/j.bbamcr.2008.09.018, 2684028, 18977398.
11. Mannova P, Fang R, Wang H, Deng B, McIntosh MW, Hanash SM, Beretta L. Modification of host lipid raft proteome upon hepatitis C virus replication. Mol Cell Proteomics 2006, 5(12):2319-2325. 10.1074/mcp.M600121-MCP200, 16943187.
12. de Laurentiis A, Donovan L, Arcaro A. Lipid rafts and caveolae in signaling by growth factor receptors. Open Biochem J 2007, 1:12-32. 2570545, 18949068.
13. Pizarro-Cerda J, Cossart P. Bacterial adhesion and entry into host cells. Cell 2006, 124(4):715-727. 10.1016/j.cell.2006.02.012, 16497583.
14. Rabilloud T. Membrane proteins and proteomics: love is possible, but so difficult. Electrophoresis 2009, 30(Suppl 1):S174-180. 10.1002/elps.200900050, 19517508.
15. Mitra SK, Goshe MB. Cysteinyl-tagging of integral membrane proteins for proteomic analysis using liquid chromatography-tandem mass spectrometry. Methods Mol Biol 2009, 528:311-326. full_text, 19153702.
16. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD, Krcova Z, Kusinska R, Ehrmann J, Buckley CD, et al. CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 2009, 7(6):787-798. 10.1158/1541-7786.MCR-08-0574, 19531562.
17. Klosek SK, Nakashiro K, Hara S, Goda H, Hasegawa H, Hamakawa H. CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. Biochem Biophys Res Commun 2009, 379(4):1097-1100. 10.1016/j.bbrc.2009.01.023, 19159612.
18. Chien CW, Lin SC, Lai YY, Lin BW, Lin SC, Lee JC, Tsai SJ. Regulation of CD151 by hypoxia controls cell adhesion and metastasis in colorectal cancer. Clin Cancer Res 2008, 14(24):8043-8051. 10.1158/1078-0432.CCR-08-1651, 19073968.
19. Zhang L, Jia X, Liu X, Sheng T, Cao R, He Q, Liu Z, Peng X, Xiong J, Zhang P, et al. Dataset of the plasma membrane proteome of nasopharyngeal carcinoma cell line HNE1 for uncovering protein function. Acta Biochim Biophys Sin (Shanghai) 2008, 40(1):55-70.
20. Cao R, Li X, Liu Z, Peng X, Hu W, Wang X, Chen P, Xie J, Liang S. Integration of a two-phase partition method into proteomics research on rat liver plasma membrane proteins. J Proteome Res 2006, 5(3):634-642. 10.1021/pr050387a, 16512679.
21. Jin J, Park J, Kim K, Kang Y, Park SG, Kim JH, Park KS, Jun H, Kim Y. Detection of differential proteomes of human beta-cells during islet-like differentiation using iTRAQ labeling. J Proteome Res 2009, 8(3):1393-1403. 10.1021/pr800765t, 19199707.
22. Guo Y, Singleton PA, Rowshan A, Gucek M, Cole RN, Graham DR, Van Eyk JE, Garcia JG. Quantitative proteomics analysis of human endothelial cell membrane rafts: evidence of MARCKS and MRP regulation in the sphingosine 1-phosphate-induced barrier enhancement. Mol Cell Proteomics 2007, 6(4):689-696. 10.1074/mcp.M600398-MCP200, 17210631.
23. Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, Keating SP, Hunter CL, Nuwaysir LM, Schaeffer DA. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 2007, 6(9):1638-1655. 10.1074/mcp.T600050-MCP200, 17533153.
24. Lu H, Yang Y, Allister EM, Wijesekara N, Wheeler MB. The identification of potential factors associated with the development of type 2 diabetes: a quantitative proteomics approach. Mol Cell Proteomics 2008, 7(8):1434-1451. 10.1074/mcp.M700478-MCP200, 2500228, 18448419.
25. Nakano K, Watanabe T, Shimizu T, Kawakami T. Immunohistochemical characteristics of bone forming cells in pleomorphic adenoma. Int J Med Sci 2007, 4(5):264-266. 2034755, 18026564.
26. Takada J, Ishii S, Ohta T, Koshiba H, Matsuyama T, Usui M, Yamawaki S, Mori M. Usefulness of a novel monoclonal antibody against human osteocalcin in immunohistochemical diagnosis. Virchows Arch A Pathol Anat Histopathol 1992, 420(6):507-511. 10.1007/BF01600255, 1609511.
27. Zheng Z, Liu Z. CD151 gene delivery activates PI3K/Akt pathway and promotes neovascularization after myocardial infarction in rats. Mol Med 2006, 12(9-10):214-220. 10.2119/2006-00037.Zheng, 1770014, 17225869.
28. Lillehoj EP, Lu W, Kiser T, Goldblum SE, Kim KC. MUC1 inhibits cell proliferation by a beta-catenin-dependent mechanism. Biochim Biophys Acta 2007, 1773(7):1028-1038. 10.1016/j.bbamcr.2007.04.009, 2349984, 17524503.
29. Hosking CR, Ulloa F, Hogan C, Ferber EC, Figueroa A, Gevaert K, Birchmeier W, Briscoe J, Fujita Y. The transcriptional repressor Glis2 is a novel binding partner for p120 catenin. Mol Biol Cell 2007, 18(5):1918-1927. 10.1091/mbc.E06-10-0941, 1855037, 17344476.
30. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics 2008, 7(10):1780-1794. 10.1074/mcp.R800002-MCP200, 2559938, 18664563.
31. Hanash SM, Pitteri SJ, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452(7187):571-579. 10.1038/nature06916, 18385731.
32. Annunen-Rasila J, Ohlmeier S, Tuokko H, Veijola J, Majamaa K. Proteome and cytoskeleton responses in osteosarcoma cells with reduced OXPHOS activity. Proteomics 2007, 7(13):2189-2200. 10.1002/pmic.200601031, 17533645.
33. Bhattacharyya S, Byrum S, Siegel ER, Suva LJ. Proteomic analysis of bone cancer: a review of current and future developments. Expert Rev Proteomics 2007, 4(3):371-378. 10.1586/14789450.4.3.371, 17552921.
34. Kang JH, Park KK, Lee IS, Magae J, Ando K, Kim CH, Chang YC. Proteome analysis of responses to ascochlorin in a human osteosarcoma cell line by 2-D gel electrophoresis and MALDI-TOF MS. J Proteome Res 2006, 5(10):2620-2631. 10.1021/pr060111i, 17022633.
35. Spreafico A, Frediani B, Capperucci C, Chellini F, Paffetti A, D'Ambrosio C, Bernardini G, Mini R, Collodel G, Scaloni A, et al. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics 2006, 6(12):3520-3532. 10.1002/pmic.200500858, 16705754.
36. Zhang YK, Zhang XH, Li JM, Sun de S, Yang Q, Diao DM. A proteomic study on a human osteosarcoma cell line Saos-2 treated with diallyl trisulfide. Anticancer Drugs 2009, 20(8):702-712. 10.1097/CAD.0b013e32832e89c7, 19550292.
37. Martyniuk CJ, Denslow ND. Towards functional genomics in fish using quantitative proteomics. Gen Comp Endocrinol 2009, 164(2-3):135-141. 10.1016/j.ygcen.2009.01.023, 19523377.
38. Latterich M, Abramovitz M, Leyland-Jones B. Proteomics: new technologies and clinical applications. Eur J Cancer 2008, 44(18):2737-2741. 10.1016/j.ejca.2008.09.007, 18977654.
39. Aggarwal K, Choe LH, Lee KH. Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 2006, 5(2):112-120. 10.1093/bfgp/ell018, 16772272.
40. Zhang LJ, Wang XE, Peng X, Wei YJ, Cao R, Liu Z, Xiong JX, Yin XF, Ping C, Liang S. Proteomic analysis of low-abundant integral plasma membrane proteins based on gels. Cell Mol Life Sci 2006, 63(15):1790-1804. 10.1007/s00018-006-6126-3, 16845608.
41. Zhang L, Wang X, Peng X, Wei Y, Cao R, Liu Z, Xiong J, Ying X, Chen P, Liang S. Immunoaffinity purification of plasma membrane with secondary antibody superparamagnetic beads for proteomic analysis. J Proteome Res 2007, 6(1):34-43. 10.1021/pr060069r, 17203946.
42. Hirano C, Nagata M, Noman AA, Kitamura N, Ohnishi M, Ohyama T, Kobayashi T, Suzuki K, Yoshizawa M, Izumi N, et al. Tetraspanin gene expression levels as potential biomarkers for malignancy of gingival squamous cell carcinoma. Int J Cancer 2009, 124(12):2911-2916. 10.1002/ijc.24297, 19330835.
43. Stickel JS, Weinzierl AO, Hillen N, Drews O, Schuler MM, Hennenlotter J, Wernet D, Muller CA, Stenzl A, Rammensee HG, et al. HLA ligand profiles of primary renal cell carcinoma maintained in metastases. Cancer Immunol Immunother 2009, 58(9):1407-1417. 10.1007/s00262-008-0655-6, 19184600.